A panelist discusses how the shift from intravenous to oral AML therapies addresses significant quality-of-life concerns by eliminating the burden of spending 7 days per month in clinics for infusions ...

A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...

A pharmacogenetics score may help physicians predict which patients with acute myeloid leukemia are more likely to respond to ...

The FDA has accepted the supplemental new drug application for decitabine/cedazuridine plus venetoclax to treat adults with AML.